Abrdn Life Sciences Investors (NYSE:HQL – Get Free Report) saw a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 96,500 shares, an increase of 94.6% from the February 13th total of 49,600 shares. Approximately 0.4% of the company’s stock are short sold. Based on an average daily trading volume, of 135,800 shares, the days-to-cover ratio is currently 0.7 days.
Abrdn Life Sciences Investors Stock Performance
Shares of HQL opened at $12.95 on Friday. The business’s fifty day moving average price is $13.67 and its 200 day moving average price is $14.25. Abrdn Life Sciences Investors has a 12-month low of $12.69 and a 12-month high of $15.90.
Abrdn Life Sciences Investors Cuts Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Friday, February 21st will be paid a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 14.52%. The ex-dividend date is Friday, February 21st.
Insider Activity
Hedge Funds Weigh In On Abrdn Life Sciences Investors
Several large investors have recently added to or reduced their stakes in HQL. Penserra Capital Management LLC bought a new stake in Abrdn Life Sciences Investors in the third quarter valued at $11,702,000. Absolute Investment Advisers LLC bought a new stake in Abrdn Life Sciences Investors in the fourth quarter valued at $5,242,000. Raymond James Financial Inc. bought a new stake in Abrdn Life Sciences Investors in the fourth quarter valued at $3,129,000. LPL Financial LLC lifted its stake in Abrdn Life Sciences Investors by 82.0% in the fourth quarter. LPL Financial LLC now owns 287,095 shares of the company’s stock valued at $3,767,000 after buying an additional 129,313 shares during the last quarter. Finally, Wolverine Asset Management LLC bought a new stake in Abrdn Life Sciences Investors in the fourth quarter valued at $1,594,000. 32.21% of the stock is currently owned by institutional investors.
About Abrdn Life Sciences Investors
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.
Featured Stories
- Five stocks we like better than Abrdn Life Sciences Investors
- What Are Some of the Best Large-Cap Stocks to Buy?
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Conference Calls and Individual Investors
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- About the Markup Calculator
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Abrdn Life Sciences Investors Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abrdn Life Sciences Investors and related companies with MarketBeat.com's FREE daily email newsletter.